CSTAR Cannabis Inc. ("CSTAR Cannabis") is pleased to announce that its application to become a Licensed Producer ("LP") under Health Canada's Access to Cannabis for Medical Purposes Regulations ("ACMPR") has progressed to the 'Active Review' Stage. This progress places CSTAR Cannabis in the final stage of the ACMPR application process, preceding the issuance of a License to Produce. Meanwhile, CSTAR Cannabis continues to work closely with Health Canada to complete its high technology production facility, designed to cultivate craft cannabis products and develop unique proprietary genetics.   

Construction at the CSTAR Cannabis Strathmore, AB facility is currently underway. Once complete, CSTAR Cannabis will submit an evidence package to Health Canada demonstrating its adherence to the ACMPR, and its readiness to begin cultivating cannabis.

"This progress represents a significant milestone for CSTAR and our shareholders. It proves that CSTAR has excellent people in place and is dedicated to executing our plan and creating shareholder value.  CSTAR continues to stay focused on our plans and timelines as we progress to full license status." said Rick Hammermeister, CEO of CSTAR Capital Inc.

About CSTAR Cannabis Inc. and CSTAR Capital Inc.

CSTAR Cannabis is a late-stage Licensed Producer ("LP") applicant, under the ACMPR, in active review with Health Canada. It is a wholly owned subsidiary of CSTAR Capital Inc. 

Located in Strathmore, Alberta, CSTAR Cannabis's facility is engineered to meet strict quality control standards and will be equipped with the latest agricultural control technology. The initial phase is expected to produce 1,000 kg of cannabis per year, with additional expansion reaching 20,000 kg per year.

CSTAR Cannabis is currently positioning itself as a craft cannabis brand, with a focus on creating unique proprietary genetics to serve both the medical and recreational markets.